Analysts predict that Dicerna Prescription drugs, Inc. (NASDAQ:DRNA) will report $81.82 million in gross sales for the present fiscal quarter, Zacks Funding Analysis stories. 5 analysts have made estimates for Dicerna Prescription drugs’ earnings, with the very best gross sales estimate coming in at $155.10 million and the bottom estimate coming in at $50.04 million. Dicerna Prescription drugs posted gross sales of $7.08 million throughout the identical quarter final 12 months, which suggests a optimistic year-over-year development fee of 1,055.6%. The corporate is scheduled to situation its subsequent earnings outcomes on Thursday, February 25th.
Based on Zacks, analysts count on that Dicerna Prescription drugs will report full-year gross sales of $196.22 million for the present fiscal 12 months, with estimates starting from $170.90 million to $278.40 million. For the subsequent monetary 12 months, analysts count on that the corporate will put up gross sales of $255.92 million, with estimates starting from $185.50 million to $358.30 million. Zacks’ gross sales calculations are a median based mostly on a survey of sell-side analysis analysts that cowl Dicerna Prescription drugs.
Dicerna Prescription drugs (NASDAQ:DRNA) final issued its quarterly earnings knowledge on Thursday, November fifth. The biopharmaceutical firm reported ($0.29) earnings per share for the quarter, lacking the Thomson Reuters’ consensus estimate of ($0.17) by ($0.12). Dicerna Prescription drugs had a adverse internet margin of 88.81% and a adverse return on fairness of 71.72%.
Plenty of analysis corporations lately commented on DRNA. BidaskClub upgraded shares of Dicerna Prescription drugs from a “promote” score to a “maintain” score in a analysis word on Thursday, October 29th. Zacks Funding Analysis upgraded Dicerna Prescription drugs from a “promote” score to a “maintain” score in a analysis report on Friday, November sixth. Lastly, SVB Leerink decreased their goal price on Dicerna Prescription drugs from $48.00 to $45.00 and set an “outperform” score for the corporate in a analysis word on Wednesday, November 25th. Two analysts have rated the stock with a maintain score and ten have issued a purchase score to the corporate. The corporate presently has a consensus score of “Purchase” and a consensus price goal of $32.60.
Dicerna Prescription drugs stock opened at $23.59 on Monday. The corporate’s 50-day transferring common price is $22.72 and its two-hundred day transferring common price is $21.38. The stock has a market cap of $1.77 billion, a price-to-earnings ratio of -14.65 and a beta of 1.40. Dicerna Prescription drugs has a 52 week low of $11.75 and a 52 week excessive of $27.68.
In associated information, COO James B. Weissman offered 8,720 shares of the enterprise’s stock in a transaction that occurred on Thursday, October 15th. The stock was offered at a median price of $20.20, for a complete transaction of $176,144.00. Following the transaction, the chief working officer now immediately owns 30,580 shares of the corporate’s stock, valued at roughly $617,716. The transaction was disclosed in a authorized submitting with the Securities & Trade Fee, which will be accessed via this hyperlink. Additionally, insider Bob D. Brown offered 8,185 shares of the stock in a transaction on Monday, November 2nd. The shares had been offered at a median price of $21.03, for a complete value of $172,130.55. Following the completion of the sale, the insider now owns 34,702 shares within the firm, valued at roughly $729,783.06. The disclosure for this sale will be discovered right here. Within the final three months, insiders have offered 80,180 shares of firm stock worth $1,781,982. Firm insiders personal 11.30% of the corporate’s stock.
Institutional buyers have lately purchased and offered shares of the corporate. Victory Capital Administration Inc. elevated its holdings in Dicerna Prescription drugs by 12.6% within the third quarter. Victory Capital Administration Inc. now owns 56,584 shares of the biopharmaceutical firm’s stock valued at $1,018,000 after shopping for an extra 6,310 shares in the course of the interval. Wells Fargo & Firm MN grew its stake in Dicerna Prescription drugs by 2.4% in the course of the third quarter. Wells Fargo & Firm MN now owns 157,473 shares of the biopharmaceutical firm’s stock valued at $2,833,000 after buying an extra 3,661 shares within the final quarter. JPMorgan Chase & Co. elevated its holdings in Dicerna Prescription drugs by 15.9% in the course of the third quarter. JPMorgan Chase & Co. now owns 593,138 shares of the biopharmaceutical firm’s stock worth $10,907,000 after buying an extra 81,449 shares in the course of the interval. Vanguard Group Inc. lifted its stake in Dicerna Prescription drugs by 13.0% within the 2nd quarter. Vanguard Group Inc. now owns 3,336,975 shares of the biopharmaceutical firm’s stock worth $84,760,000 after buying an extra 385,118 shares within the final quarter. Lastly, American Worldwide Group Inc. boosted its holdings in Dicerna Prescription drugs by 25.6% within the 2nd quarter. American Worldwide Group Inc. now owns 39,730 shares of the biopharmaceutical firm’s stock valued at $1,009,000 after buying an extra 8,101 shares in the course of the interval. 74.95% of the stock is presently owned by institutional buyers.
Dicerna Prescription drugs Firm Profile
Dicerna Prescription drugs, Inc, a biopharmaceutical firm, focuses on the invention and improvement of ribonucleic acid interference (RNAi)-based prescribed drugs. The corporate develops prescribed drugs utilizing its GalXC RNAi platform for the therapy of illnesses involving the liver, together with uncommon illnesses, viral infectious illnesses, continual liver illnesses, and cardiometabolic illnesses.
Featured Story: Stock Market – What’s a circuit breaker?
Get a free copy of the Zacks analysis report on Dicerna Prescription drugs (DRNA)
For extra details about analysis choices from Zacks Funding Analysis, go to Zacks.com
This instantaneous information alert was generated by narrative science know-how and monetary knowledge from MarketBeat with a purpose to present readers with the quickest and most correct reporting. This story was reviewed by MarketBeat’s editorial workforce previous to publication. Please ship any questions or feedback about this story to [email protected]